Exploring the effects of suvorexant on sleep and blood biomarkers in Alzheimer's disease

UMIN ID: UMIN000054123

Registered date:11/04/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Alzheimer's disease
• Date of first enrollment: 2024/04/11
• Target sample size: 15
• Countries of recruitment: Japan
• Study type: Interventional
• Intervention(s): Administration of suvorexant

Outcome(s)

• Primary Outcome: Percentage of REM sleep duration and amyloid-beta 42/40 ratio before and after administration of suvorexant

Key inclusion & exclusion criteria

• Age minimum: 65years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: 1, Comorbid dementia other than Alzheimer's disease. 2, Comorbid schizophrenia, mood disorder, anxiety disorder, drug/substance addiction, or personality disorder. 3, Serious physical illnesses such as cerebrovascular disease, cardiac disease, renal dysfunction, and neurological disease. 4, The patient has a coexisting sleep-related breathing disorder (respiratory event index of 10 or more on the apnomonitor). 5, The principal investigator or attending physician determines that the subject is unsuitable for the study.

Related Information

• Primary Sponsor: Kurita hospital
• Source(s) of Monetary Support: Nothing